(NP (NP Structure/NN function/NN analysis/NN) (PP of/IN (NP (NP vitamin/NN D/NN analogs/NNS) (PP with/IN (NP C-ring/NN modifications/NNS)))) ./.)
(S (NP-SBJ-52 (NP Analogs/NNS) (PP of/IN (NP (NP 1/CD alpha,25-dihydroxyvitamin/NN D3/NN) (PRN -LRB-/-LRB- (NP 1/CD alpha,25--LRB-OH-RRB-/NN 2D3/NN) -RRB-/-RRB-))) (PP with/IN (NP (NP substitutions/NNS) (PP on/IN (NP C-11/NN))))) (VP were/VBD (VP synthesized/VBN (NP *-52/-NONE-))) ./.)
(S-COOD (S (NP-SBJ (NP Small/JJ apolar/JJ substitutions/NNS) (PRN -LRB-/-LRB- (NP-COOD (NP 11/CD alpha-methyl/NN) ,/, (NP 11/CD alpha-fluoromethyl/NN)) -RRB-/-RRB-)) (VP did/VBD not/RB (ADVP markedly/RB) (VP decrease/VB (NP (NP the/DT affinity/NN) (PP for/IN (NP the/DT vitamin/NN D/NN receptor/NN)))))) ,/, but/CC (S (NP-SBJ (NP (ADJP-COOD (ADJP larger/JJR (PRN -LRB-/-LRB- (NP-COOD (NP 11/CD alpha-chloromethyl/NN) or/CC (NP (NP 11/CD alpha-/NN) or/CC 11/CD beta-phenyl/NN)) -RRB-/-RRB-)) or/CC (ADJP more/RBR polar/JJ)) substitutions/NNS) (PRN -LRB-/-LRB- (NP-COOD (NP 11/CD alpha-hydroxymethyl/NN) ,/, (NP 11/CD alpha--LRB-2-hydroxyethyl/NN)) -RCB-/-RRB-)) (VP decreased/VBD (NP the/DT affinity/NN) (PP to/TO (NP (NP (QP less/JJR than/IN 5/CD) %/NN) (PP of/IN (NP (NP that/DT) (PP of/IN (NP 1/CD alpha,25-OH-RRB-2D3/NN)))))))) ./.)
(S (NP-SBJ (NP Their/PRP$ affinity/NN) (PP for/IN (NP the/DT (ADJP vitamin/NN D-binding/JJ) protein/NN))) ,/, (ADVP however/RB) ,/, (VP increased/VBD (ADVP up/RB to/TO 4-fold/RB)) ./.)
(S-COOD (S (NP-SBJ (NP The/DT biological/JJ activity/NN) (PP of/IN (NP 11/CD alpha-methyl-1/NN alpha,25--LRB-OH-RRB-2D3/NN))) (ADVP closely/RB) (VP resembled/VBD (NP (NP that/DT) (PP of/IN (NP the/DT natural/JJ hormone/NN)) (PP on/IN (NP (ADJP-COOD (ADJP normal/JJ) and/CC (ADJP leukemic/JJ)) (NP-COOD (NP cell/NN proliferation/NN) and/CC (NP bone/NN resorption/NN))))))) ,/, whereas/IN (S (NP-SBJ (NP its/PRP$ (ADJP in/FW vivo/FW) effect/NN) (PP on/IN (NP (NP calcium/NN metabolism/NN) (PP of/IN (NP the/DT rachitic/JJ chick/NN))))) (VP was/VBD (NP-PRD (NP (QP about/IN 50/CD) %/NN) (PP of/IN (NP (NP that/DT) (PP of/IN (NP 1/CD alpha,25--LRB-OH-RRB-2D3/NN))))))) ./.)
(S (NP-SBJ The/DT 11/CD beta-methyl/NN analog/NN) (VP had/VBD (NP a/DT (ADJP (ADVP greater/JJR than/IN 10-fold/RB) lower/JJR) activity/NN)) ./.)
(S-COOD (S (NP-SBJ (NP The/DT differentiating/JJ effects/NNS) (PP of/IN (NP the/DT other/JJ C-11/NN analogs/NNS)) (PP on/IN (NP (NP human/JJ promyeloid/JJ leukemia/NN cells/NNS) (PRN -LRB-/-LRB- (NP HL-60/NN) -RRB-/-RRB-)))) (VP agreed/VBD (ADVP well/RB) (PP with/IN (NP their/PRP$ (NP-COOD (NP bone-resorbing/JJ activity/NN) and/CC (NP receptor/NN affinity/NN)))))) ,/, but/CC (S (NP-SBJ they/PRP) (VP demonstrated/VBD (NP lower/JJR calcemic/JJ effects/NNS) (ADVP in/FW vivo/FW))) ./.)
(S (NP-SBJ (NP (ADJP-COOD (ADJP Large/JJ) or/CC (ADJP polar/JJ)) substitutions/NNS) (PP on/IN (NP (NP C-11/NN) (PP of/IN (NP 1/CD alpha,25--LRB-OH-RRB-2D3/NN))))) (ADVP thus/RB) (VP-COOD (VP impair/VBP (NP (NP the/DT binding/NN) (PP of/IN (NP the/DT vitamin/NN D/NN receptor/NN)))) but/CC (VP increase/VBP (NP (NP the/DT affinity/NN) (PP to/TO (NP (ADJP vitamin/NN D-binding/JJ) protein/NN))))) ./.)
(S (NP-SBJ (NP The/DT effects/NNS) (PP of/IN (NP many/JJ C-11-substituted/JJ 1/CD alpha,25--LRB-OH-RRB-2D3/NN analogs/NNS)) (PP on/IN (NP HL-60/NN cell/NN differentiation/NN))) (VP exceeded/VBD (NP (NP their/PRP$ activity/NN) (PP on/IN (NP calcium/NN metabolism/NN)))) ./.)
